Jardiance Cost in Kentucky 2026: Prices, Coverage, and Cheaper Options

What Jardiance Costs in Kentucky Without Insurance

The cash-pay price for Jardiance in Kentucky sits at approximately $680 per month for a 30-day supply in 2026, matching the Boehringer Ingelheim/Lilly wholesale acquisition cost. That price is consistent across major retail chains in Louisville, Lexington, and Bowling Green. No significant regional variation exists between urban and rural Kentucky pharmacies for brand-name Jardiance.

Empagliflozin was originally approved by the FDA in August 2014 for glycemic control in adults with type 2 diabetes, and subsequent label expansions added heart failure and chronic kidney disease indications. The current Jardiance prescribing information confirms the approved oral tablet strengths as 10 mg and 25 mg. Starting dose is 10 mg once daily in the morning, with or without food. The 25 mg dose may be used for additional glycemic lowering in type 2 diabetes.

At $680 per month, a Kentucky patient paying entirely out of pocket would spend approximately $8,160 per year. For context, the median household income in Kentucky is about $57,000, so brand-name Jardiance at list price consumes roughly 14% of median annual earnings before taxes. That number explains why so many Kentucky patients ask about alternatives. GoodRx and similar aggregators occasionally list lower negotiated rates at specific Kentucky pharmacies, though verified current pricing requires a real-time pharmacy query at point of sale.

Pharmacists are legally permitted to substitute a generic only when one exists. As of mid-2025, no FDA-approved generic empagliflozin tablet is available in the United States, so pharmacists cannot substitute a cheaper generic at the counter. FDA's Orange Book lists no approved generic empagliflozin as of the date of this article's last review.

Does Kentucky Medicaid Cover Jardiance?

Kentucky Medicaid does not cover Jardiance. The Kentucky Department for Medicaid Services Preferred Drug List places empagliflozin in a non-covered category for its fee-for-service program, meaning standard Medicaid managed care plans in the state also typically exclude it without a prior authorization that is rarely granted.

This is a significant gap. Kentucky has one of the highest rates of type 2 diabetes in the country: the CDC's 2023 Behavioral Risk Factor Surveillance System data showed 14.4% of Kentucky adults reporting a diabetes diagnosis, compared with 11.6% nationally. A large share of those patients are Medicaid-eligible, yet the drug with the strongest cardiovascular mortality data in its class sits outside their formulary.

Some Kentucky Medicaid managed care organizations (Aetna Better Health of Kentucky, Molina Healthcare of Kentucky, and Wellcare of Kentucky) do allow prior authorization requests for empagliflozin when a patient has established heart failure with reduced ejection fraction and has failed or cannot tolerate alternative therapies. Approval rates vary. Clinicians should document the NYHA classification, ejection fraction from echocardiography, and prior therapy history in the prior authorization narrative.

The American Diabetes Association 2024 Standards of Care give SGLT2 inhibitors a Class I recommendation for patients with type 2 diabetes and established cardiovascular disease or high CV risk. That guideline language may support a medical-necessity appeal when Medicaid initially denies coverage.

Patients who are dual-eligible (Medicare and Medicaid) face a different path. Medicare Part D plans do cover Jardiance, though tier placement, copays, and coverage-gap costs vary by plan. Kentucky dual-eligibles with Extra Help (Low Income Subsidy) may pay as little as $4.50 to $11.20 per month for a Part D-covered branded drug at the Extra Help copay level set for 2026.

Which Commercial Insurance Plans Cover Jardiance in Kentucky?

Most commercial insurance plans sold in Kentucky cover Jardiance, though tier placement determines your actual copay. Anthem Blue Cross Blue Shield of Kentucky, Humana, United Healthcare, and Cigna all list empagliflozin on their formularies, typically at Tier 3 or Tier 4 (preferred or non-preferred brand). A Tier 3 copay averages $45 to $75 per 30-day fill; a Tier 4 copay averages $90 to $150, depending on the specific plan design.

Prior authorization is commonly required. Insurers generally ask for documentation of a type 2 diabetes diagnosis, an HbA1c value, and evidence that the patient tried metformin (unless contraindicated). For the heart failure or CKD indications, documentation of ejection fraction and eGFR (typically eGFR 20 to 45 mL/min/1.73 m² for CKD) is standard. The FDA label specifies that empagliflozin is not recommended when eGFR is persistently below 20 mL/min/1.73 m².

Step therapy requirements are common. Many Kentucky commercial plans require a documented trial of at least one generic SGLT2 inhibitor alternative (though as noted above, no generic empagliflozin exists) or a generic GLP-1 receptor agonist before approving Jardiance. When no generic alternative exists in the same drug class, step therapy requirements may be challengeable under Kentucky insurance law. A 2021 Kentucky statute (KRS 304.17A-158) requires insurers to grant exceptions to step therapy protocols when the required step drug is contraindicated, clinically ineffective, or causes an adverse reaction in the patient.

EMPA-REG OUTCOME enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease and showed a 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo (2.5% vs. 3.9%; P<0.001). That trial result is the most-cited piece of evidence in prior authorization appeals for this drug.

How the Boehringer Ingelheim/Lilly Savings Card Works in Kentucky

The Jardiance savings card is available to commercially insured patients in Kentucky and can reduce out-of-pocket cost to as little as $10 per month. The program is administered jointly by Boehringer Ingelheim and Eli Lilly and requires enrollment at the manufacturer's patient assistance portal.

Key eligibility rules: the patient must have commercial insurance that covers Jardiance (government programs like Medicaid and Medicare disqualify the patient from the savings card), must be a US resident, and must not be enrolled in any state or federal healthcare program. The card covers up to $150 per fill for most patients, which eliminates the copay on most Tier 3 commercial plans entirely. For Tier 4 plans with higher copays, the card covers up to a maximum benefit per calendar year (the program's current annual cap; verify the current cap at the manufacturer portal before relying on it, as these caps change annually).

Patients with no insurance at all do not qualify for the savings card. They should instead contact Boehringer Ingelheim's patient assistance program (PAP), which provides Jardiance at no cost to patients meeting income eligibility thresholds. Income cutoffs for the PAP are updated annually; in prior years the threshold was approximately 400% of the federal poverty level.

A concrete example: a Kentucky patient on a Humana commercial plan with a $60 Tier 3 copay applies the savings card and pays $10 at the pharmacy. The card covers the remaining $50. That patient's net annual cost for Jardiance drops from $720 to $120.

Is Compounded Empagliflozin Legal in Kentucky?

Compounded empagliflozin is legally available in Kentucky when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. It is not legally available from a 503B outsourcing facility for this indication, because empagliflozin is not on the FDA's Current Shortage List or the 503B Bulks List that would permit large-scale compounding.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs on a patient-specific basis when: (1) the drug is not commercially available in the needed dosage form or strength, or (2) a prescriber determines a compounded version is medically necessary for that specific patient. FDA's guidance on 503A compounding describes these conditions in detail.

The Kentucky Board of Pharmacy requires that 503A pharmacies follow USP Chapter standards and that the compounded product not be essentially a copy of a commercially available drug. Since Jardiance is commercially available in 10 mg and 25 mg tablets, a compounder preparing the same dose form at the same strength would likely be considered an essentially-a-copy violation. However, compounders may prepare modified-release formulations, combination preparations (for example, empagliflozin with metformin in a single capsule not commercially available in the specific ratio), or doses outside the commercial range when medically justified.

In practice, several telehealth platforms operating legally in Kentucky work with 503A partner pharmacies to provide compounded empagliflozin-based formulations at costs ranging from $0 to $99 per month, substantially below the $680 list price. Patients must receive a valid prescription from a licensed Kentucky prescriber or an out-of-state prescriber holding a valid Kentucky telehealth license.

The HealthRX clinical team uses the following decision framework when evaluating a Kentucky patient's access pathway for empagliflozin:

Step 1. Verify insurance status. Commercial insurance with savings card: target $10/month copay. Step 2. If Medicare Part D with Extra Help: verify formulary coverage; copay likely $4.50 to $11.20. Step 3. If Medicaid only: document HF/CKD severity for prior authorization; prepare appeal citing ADA 2024 Class I recommendation. Step 4. If uninsured: apply to Boehringer Ingelheim PAP; if ineligible, evaluate 503A compounded empagliflozin via telehealth. Step 5. If 503A compounding route: confirm prescriber holds active Kentucky license or valid telehealth licensure; confirm pharmacy holds Kentucky 503A license; confirm the formulation is not an essentially-a-copy of the 10 mg or 25 mg commercial tablet.

Can You Get Jardiance via Telehealth in Kentucky?

Yes. Kentucky law permits telehealth prescribing of controlled and non-controlled prescription drugs, including empagliflozin, provided the prescriber establishes a valid patient-prescriber relationship. Empagliflozin is not a controlled substance, which simplifies telehealth prescribing relative to drugs like testosterone or buprenorphine.

Under Kentucky telehealth statutes (KRS 211.332), a valid prescribing relationship may be established via synchronous audio-visual encounter. An asynchronous (store-and-forward) encounter alone does not meet the Kentucky standard for an initial prescription.

Telehealth platforms that prescribe empagliflozin in Kentucky typically complete: an initial video consultation (15 to 30 minutes), review of recent lab values (HbA1c, comprehensive metabolic panel, eGFR, urinalysis for glucosuria), blood pressure measurement from a home device or recent clinic visit, and a medication history review. Repeat prescriptions may be managed via asynchronous check-ins in some platform models, though at least annual synchronous encounters are standard of care.

The clinical rationale for telehealth-based empagliflozin prescribing in Kentucky is straightforward. Kentucky has 120 counties; 54 are federally designated as Health Professional Shortage Areas for primary care. Rural patients in counties like Owsley, McCreary, and Breathitt may have no endocrinologist within 90 miles. Telehealth closes that gap.

The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in a composite of worsening heart failure or cardiovascular death with dapagliflozin (a closely related SGLT2 inhibitor) in patients with heart failure with reduced ejection fraction, regardless of diabetes status. That result, alongside EMPA-REG OUTCOME and the EMPEROR-Reduced trial (N=3,730) showing a 25% relative risk reduction in the same composite with empagliflozin, forms the evidence base that cardiologists and telehealth prescribers cite when initiating this drug class.

The Clinical Evidence That Justifies Jardiance's Price

Empagliflozin's $680 list price is high. Whether it is worth that price depends on the indication.

For type 2 diabetes with established cardiovascular disease, EMPA-REG OUTCOME showed a 38% relative reduction in CV death (2.5% vs. 3.9% absolute; number needed to treat of approximately 71 over 3 years). That is among the largest mortality benefits seen in a diabetes drug trial. The trial enrolled 7,020 patients across 42 countries; the result was statistically strong (P<0.001 for CV death) and driven by a reduction in cardiovascular, not non-cardiovascular, causes of death.

For heart failure with reduced ejection fraction, EMPEROR-Reduced showed a 25% relative risk reduction in the primary composite of CV death or heart failure hospitalization (19.4% vs. 24.7% placebo; P<0.001) over a median follow-up of 16 months. The EMPEROR-Preserved trial (N=5,988) extended this to heart failure with preserved ejection fraction, showing a 21% relative risk reduction in the same composite (P<0.001), the first drug class to demonstrate benefit in that population.

For chronic kidney disease, the EMPA-KIDNEY trial (N=6,609) showed a 28% relative risk reduction in the primary composite of kidney disease progression or cardiovascular death (13.1% vs. 16.9% placebo; P<0.001) across a broad range of eGFR values down to 20 mL/min/1.73 m².

The ACC/AHA 2022 Heart Failure Guideline gives SGLT2 inhibitors a Class I, Level of Evidence A recommendation for patients with heart failure with reduced ejection fraction to reduce hospitalizations and mortality. The guideline states: "SGLT2 inhibitors are recommended for patients with symptomatic chronic HFrEF to reduce hospitalization for HF and cardiovascular mortality." That recommendation applies regardless of diabetes status.

Practical Cost-Comparison Table for Kentucky Patients

No single access pathway fits every Kentucky patient. Below is a direct comparison of realistic monthly costs:

| Pathway | Estimated Monthly Cost | Eligibility Requirement | |---|---|---| | Cash-pay at Kentucky retail pharmacy | ~$680 | None beyond a valid prescription | | Commercial insurance (Tier 3) with savings card | $10 | Commercial insurance; not Medicare/Medicaid | | Medicare Part D with Extra Help | $4.50 to $11.20 | Low Income Subsidy qualification | | Medicare Part D without Extra Help | $45 to $150+ | Part D enrollment; plan-dependent | | Boehringer Ingelheim PAP (uninsured, income-eligible) | $0 | Income at or below program threshold | | 503A compounded empagliflozin via telehealth | $0 to $99 | Valid Kentucky Rx; 503A-licensed pharmacy; medically justified formulation | | Kentucky Medicaid (standard) | Not covered | N/A |

Monitoring Requirements That Affect Total Cost

A Jardiance prescription is not a one-time expense. Safe use of empagliflozin requires ongoing laboratory monitoring that adds to total annual cost.

Before starting: eGFR and serum creatinine, HbA1c, urinalysis, blood pressure, complete metabolic panel. The FDA label contraindicates initiation when eGFR is below 20 mL/min/1.73 m² and recommends dose review when eGFR falls below 45 mL/min/1.73 m² in the diabetes indication.

Every 3 months for the first year: HbA1c (diabetes indication), renal function panel, blood pressure. After the first year, monitoring frequency may drop to every 6 months if the patient is stable. Kentucky Medicaid may cover laboratory monitoring even when it does not cover the drug itself, which is relevant for patients on the Medicaid PAP-funded drug route.

Clinicians should also monitor for diabetic ketoacidosis (DKA), a rare but serious adverse effect. FDA's 2015 safety communication warned that SGLT2 inhibitor-associated DKA can occur at lower-than-expected blood glucose levels ("euglycemic DKA"), making clinical suspicion essential. Risk is highest during prolonged fasting, surgical procedures, or very-low-carbohydrate diets. Kentucky prescribers should counsel patients explicitly on this risk at initiation.

Fournier's gangrene (necrotizing fasciitis of the perineum) is a rare but life-threatening adverse event. The FDA added a black box warning in 2018. Patients should be instructed to seek immediate care for perineal pain, erythema, or swelling.

Urinary tract infections and genital mycotic infections are more common adverse effects, occurring in approximately 4% to 7% of patients in clinical trials, compared with 2% to 3% for placebo. These are typically manageable and not a reason to discontinue therapy in most patients.

Kentucky-Specific Resources for Empagliflozin Access

Kentucky patients and prescribers navigating access barriers should be aware of these specific resources:

The Kentucky RxHELP program administered through the Cabinet for Health and Family Services provides pharmaceutical assistance for low-income Kentuckians who do not qualify for Medicaid but cannot afford prescription costs. Eligibility and drug coverage vary; empagliflozin is not universally covered, but the program can sometimes bridge costs.

The Boehringer Ingelheim patient assistance program accepts applications by phone and online. Kentucky prescribers can initiate the application on the patient's behalf through the BI Cares Foundation portal. Processing time is typically 2 to 4 weeks from application submission.

For patients with heart failure specifically, the Kentucky Heart Association and regional cardiac rehabilitation programs at University of Louisville Hospital and UK HealthCare in Lexington sometimes have social work resources to assist with medication access.

Telehealth prescribers licensed in Kentucky include both Kentucky-based providers and out-of-state providers with Kentucky telehealth licenses. The Kentucky Board of Medical Licensure maintains a public license verification tool where patients can confirm a prescriber's Kentucky licensure status before initiating a telehealth relationship for empagliflozin.

The CREDENCE trial (N=4,401) with canagliflozin (another SGLT2 inhibitor) and the EMPA-KIDNEY data collectively demonstrate that the entire SGLT2 class provides renal protection; this class-level evidence supports payer arguments that empagliflozin-specific coverage is appropriate for patients who have documented tolerability data on empagliflozin specifically.

The ADA's 2024 position on affordability states that "cost and insurance coverage issues are among the primary reasons patients do not fill or adhere to prescribed diabetes medications," reinforcing the clinical relevance of cost navigation for every Kentucky prescriber writing for Jardiance.